Abstract 4158
Background
Tumor-associated macrophages (TAMs) constitute over 50% of the number of cells in breast malignancies. In mouse models, most TAMs in the breast cancer microenvironment behave as the M2-like phenotype, with protumor characteristics, but the roles of TAMs in human breast cancer are poorly understand. Specific TAMs related molecular mechanisms among different intrinsic molecular subtypes remain unclear. Here, we focused on studying protumor TAM markers among human breast cancer tissues: CD163, CD204, CD206 which commonly used in mouse models. We identify and explore roles of TAMs novel marker: CD204 in intrinsic molecular subtypes of breast cancer.
Methods
Expression of CD204, CD163, CD206 and clinical outcome of CD204 were analyzed using The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets. Potential Kyoto Encyclopedia of Genes and Genomes (KEGG) and HALLMARK pathways regulated by CD204 were studied using Gene Set Enrichment Analysis (GSEA). We used CIBERSOT to estimate the immune contextures regulated by CD204 among different subtypes and the correlations of CD204 and immune suppressive molecules were also analyzed.
Results
Compared to CD163, CD206, only CD204 was found upregulated in breast cancer compared to the normal tissue, associated with poor OS, RFS, and DMFS. The expression of CD204 was different between 4 subtypes. CD204 was involved in immune system-related pathways including innate and adaptive immunity among all subtypes. Numerous special pathways were also found influenced by CD204: tumor metabolism-related pathways in luminal A, Hippo and TGF-β signaling pathways in luminal B, cell cycle process in HER-2 amplified, and RIG-I-like receptor signaling pathway in basal-like subtype. Strong correlations between CD204 and immune cells especially for protumor populations were displayed, and most immunosuppressive molecules: HIF1A, FAP, IL10, PDCD1/CD274, CTLA4, HAVCR2, positive correlated with CD204 expression in all subtypes.
Conclusions
CD204 could become an applicable marker of TAMs in human breast cancer. These findings contribute to better understanding and managing of TAMs in different subtypes of breast cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Jinhai Tang.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2344 - Lung Cancer in Europe: strengthening policy responses to address unmet needs
Presenter: Mary Bussell
Session: Poster Display session 3
Resources:
Abstract
1359 - Curative treatment timelines for breast, colorectal, lung and prostate cancer: Implications for medical leave coverage
Presenter: Selina Wong
Session: Poster Display session 3
Resources:
Abstract
4433 - Acute Diagnostic Oncology Clinic: A Unique Primary Care-Oncology Service
Presenter: Abhijit Gill
Session: Poster Display session 3
Resources:
Abstract
3506 - THE NEW MUTATIONAL MODEL IN ONCOLOGY. What changes in welfare, clinical practice, research, and regulatory procedures
Presenter: Nicola Normanno
Session: Poster Display session 3
Resources:
Abstract
3350 - Selection of a set of quality indicators (QI) for oncological clinical pathway
Presenter: Aude Fourcade
Session: Poster Display session 3
Resources:
Abstract
4400 - Sustainable drug prices at market launch: policy proposals and their empirical evidence
Presenter: Nora Fanzen
Session: Poster Display session 3
Resources:
Abstract
4118 - Impact of financial considerations on French physicians’ prescription choices for advanced non-small cell lung cancer (NSCLC)
Presenter: Nathalie Olympios
Session: Poster Display session 3
Resources:
Abstract
1340 - The direct medical cost of breast cancer in a Belgian hospital
Presenter: Hannan Lemhouer
Session: Poster Display session 3
Resources:
Abstract
1863 - Does the healthcare system approaches cancer patients for using private services during diagnostic process?
Presenter: Karolina Osowiecka
Session: Poster Display session 3
Resources:
Abstract
2637 - Measuring financial toxicity of cancer in the Italian health care system: initial results of the patient reported outcome for Fighting Financial Toxicity of cancer project (proFFiT).
Presenter: Silvia Riva
Session: Poster Display session 3
Resources:
Abstract